EPYC

Summary

EPYC (epiphycan, HGNC:3053) is a protein-coding gene on chromosome 12q21.33, encoding Epiphycan (Q99645). May have a role in bone formation and also in establishing the ordered structure of cartilage through matrix organization.

Dermatan sulfate proteoglycan 3 is a member of the small leucine-rich repeat proteoglycan family. This gene is composed of seven exons. It regulates fibrillogenesis by interacting with collagen fibrils and other extracellular matrix proteins.

Source: NCBI Gene 1833 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 67 total
• MANE Select transcript: NM_004950

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3053
Approved symbol	EPYC
Name	epiphycan
Location	12q21.33
Locus type	gene with protein product
Status	Approved
Aliases	Pg-Lb, SLRR3B
Ensembl gene	ENSG00000083782
Ensembl biotype	protein_coding
OMIM	601657
Entrez	1833

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron

ENST00000261172, ENST00000550203, ENST00000551767

RefSeq mRNA: 1 — MANE Select: NM_004950 NM_004950

CCDS: CCDS31870

Canonical transcript exons

ENST00000261172 — 7 exons

Exon	Start	End
ENSE00000752986	90970044	90970139
ENSE00000752987	90972822	90972980
ENSE00001098688	90963682	90964326
ENSE00001098691	91002401	91002578
ENSE00003653434	90978088	90978262
ENSE00003789039	90971800	90972002
ENSE00003844738	91004947	91004972

Expression profiles

Bgee: expression breadth broad, 61 present calls, max score 96.40.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 5.2844 / max 507.4572, expressed in 114 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
132531	4.7416	110
132532	0.4478	74
132530	0.0950	48

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cartilage tissue	UBERON:0002418	96.40	gold quality
tibia	UBERON:0000979	95.27	gold quality
decidua	UBERON:0002450	94.89	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.99	gold quality
stromal cell of endometrium	CL:0002255	65.74	gold quality
placenta	UBERON:0001987	61.53	gold quality
pancreatic ductal cell	CL:0002079	60.82	silver quality
hair follicle	UBERON:0002073	52.43	gold quality
mucosa of stomach	UBERON:0001199	51.73	gold quality
gall bladder	UBERON:0002110	51.71	gold quality
epithelial cell of pancreas	CL:0000083	51.34	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
quadriceps femoris	UBERON:0001377	50.01	gold quality
metanephric glomerulus	UBERON:0004736	49.61	gold quality
ileal mucosa	UBERON:0000331	49.45	silver quality
vastus lateralis	UBERON:0001379	49.45	gold quality
layer of synovial tissue	UBERON:0007616	49.45	silver quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
thymus	UBERON:0002370	49.28	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
left ventricle myocardium	UBERON:0006566	48.24	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	2218.10
E-ANND-3	yes	3.26

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): SOX9

miRNA regulators (miRDB)

34 targeting EPYC, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-7978	99.86	66.90	856
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-12129	99.72	67.45	1311
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-372-5P	99.41	69.11	2299
HSA-MIR-3606-5P	99.31	69.67	1168
HSA-MIR-3973	99.20	69.19	1990
HSA-MIR-4528	99.18	69.77	1936
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-371A-5P	99.08	66.51	1914
HSA-MIR-299-5P	98.56	71.14	1140
HSA-MIR-7852-3P	98.37	67.98	823
HSA-MIR-124-5P	98.11	67.65	1095
HSA-MIR-6783-5P	97.67	67.21	1528
HSA-MIR-6818-5P	97.50	67.10	1167

Literature-anchored findings (GeneRIF, showing 5)

• In addition, no pathogenic sequence variations were found in DCN, DSPG3, LUM, PITX2 and FOXC1, which have also been implicated in corneal and anterior segment dysgenesis. (PMID:17558846)
• OPTC and EPYC are unlikely to play a major role in high myopia. (PMID:19844586)
• Linkage and haplotype analyses identified 12q21.33 as a locus for posterior amorphous corneal dystrophy. However, no mutations were identified in the candidate genes (KERA, LUM, DCN, EPYC) within this region. (PMID:20357198)
• KLF9 and EPYC acting as feature genes for osteoarthritis and their association with immune infiltration. (PMID:35902862)
• EPYC functions as a novel prognostic biomarker for pancreatic cancer. (PMID:38184732)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	epyc	ENSDARG00000056950
mus_musculus	Epyc	ENSMUSG00000019936
rattus_norvegicus	Epyc	ENSRNOG00000004717

Paralogs (10): OGN (ENSG00000106809), ECM2 (ENSG00000106823), FMOD (ENSG00000122176), OMG (ENSG00000126861), OMD (ENSG00000127083), LUM (ENSG00000139329), KERA (ENSG00000139330), PRELP (ENSG00000188783), LINGO4 (ENSG00000213171), LINGO3 (ENSG00000220008)

Protein

Protein identifiers

Epiphycan — Q99645 (reviewed: Q99645)

Alternative names: Dermatan sulfate proteoglycan 3, Proteoglycan-Lb, Small chondroitin/dermatan sulfate proteoglycan

All UniProt accessions (2): Q99645, F8VSI4

UniProt curated annotations — full annotation on UniProt →

Function. May have a role in bone formation and also in establishing the ordered structure of cartilage through matrix organization.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Cartilage, ligament, and placenta.

Post-translational modifications. The O-linked polysaccharides on Thr-60 and Ser-96 are probably the mucin type linked to GalNAc. There is one glycosaminoglycan chain, known to be dermatan sulfate, and it is probably the O-glycosylation at Ser-64.

Similarity. Belongs to the small leucine-rich proteoglycan (SLRP) family. SLRP class III subfamily.

RefSeq proteins (1): NP_004941* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR043547	Mimecan/Epiphycan/Opticin	Family

Pfam: PF00560, PF01462, PF13855

UniProt features (23 total): repeat 6, glycosylation site 5, sequence conflict 5, disulfide bond 2, signal peptide 1, chain 1, sequence variant 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99645-F1	76.83	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 118–130, 279–312

Glycosylation sites (5): 60, 64, 96, 283, 302

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 77 (showing top): GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOBP_BONE_DEVELOPMENT, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM5, chr12q21, GOBP_MULTI_MULTICELLULAR_ORGANISM_PROCESS, GOMF_GLYCOSAMINOGLYCAN_BINDING, AFP1_Q6, AACTTT_UNKNOWN, GOBP_SENSORY_PERCEPTION, GOBP_CONNECTIVE_TISSUE_DEVELOPMENT, FREAC7_01, TGGAAA_NFAT_Q4_01, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_DN

GO Biological Process (4): female pregnancy (GO:0007565), sensory perception of sound (GO:0007605), bone development (GO:0060348), articular cartilage development (GO:0061975)

GO Molecular Function (2): glycosaminoglycan binding (GO:0005539), protein binding (GO:0005515)

GO Cellular Component (2): extracellular matrix (GO:0031012), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
multi-organism reproductive process	1
multi-multicellular organism process	1
sensory perception of mechanical stimulus	1
skeletal system development	1
animal organ development	1
cartilage development	1
carbohydrate derivative binding	1
binding	1
external encapsulating structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1098 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EPYC	BGN	P13247	622
EPYC	LUM	P51884	602
EPYC	LNPEP	Q9UIQ6	582
EPYC	MATN4	O95460	560
EPYC	HSPG2	P98160	557
EPYC	FMOD	Q06828	556
EPYC	STT3B	Q8TCJ2	507
EPYC	NYX	Q9GZU5	490
EPYC	ACAN	P16112	483
EPYC	FN1	P02751	480
EPYC	ASPN	Q9BXN1	480
EPYC	STT3A	P46977	477
EPYC	TGFBI	Q15582	471
EPYC	ECM2	O94769	465
EPYC	THBS4	P35443	465

IntAct

7 interactions, top by confidence:

A	B	Type	Score
CRK	EPYC	psi-mi:“MI:0915”(physical association)	0.490
EPYC	PLCG2	psi-mi:“MI:0915”(physical association)	0.490
		psi-mi:“MI:0914”(association)	0.350

BioGRID (3): EPYC (Two-hybrid), EPYC (Two-hybrid), EPYC (Synthetic Lethality)

ESM2 similar proteins: A0N0X6, B1H134, B1H234, D3ZAL8, D3ZTV3, F1NUK7, O43155, O94769, O94991, P28653, P58874, P70186, P79119, Q32Q07, Q3MHH9, Q3SXY7, Q504C1, Q5FW85, Q5R482, Q5R6T0, Q5R7M3, Q5RAC4, Q61809, Q6RKD8, Q6UXK5, Q70AK3, Q7TNJ4, Q80ZD9, Q810B7, Q810B8, Q810C0, Q810C1, Q86SJ2, Q86VH5, Q8BGT1, Q8BLU0, Q8BZ81, Q8C110, Q8CBC6, Q8IW52

Diamond homologs: A3KNN3, A6H789, A6H793, A6NJW4, A8WHP9, E7FE13, F1MLX5, G5EFX6, O02678, O02833, O35367, O46378, O46379, O46542, O60938, O62702, O75093, O75094, O88279, O88280, O94813, P07359, P07585, P21793, P24014, P28654, P28675, P35858, P35859, P51884, P51885, P51886, P51888, P51890, P58874, P59034, P59035, P70186, P70389, P83286

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	55
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

859 predictions. Top by Δscore:

Variant	Effect	Δscore
12:90964325:TT:T	acceptor_gain	1.0000
12:90964327:C:CC	acceptor_gain	1.0000
12:90969700:C:CA	donor_gain	1.0000
12:90971796:TTA:T	donor_loss	1.0000
12:90971797:TA:T	donor_loss	1.0000
12:90971798:A:AC	donor_gain	1.0000
12:90971799:C:A	donor_loss	1.0000
12:90971799:C:CA	donor_gain	1.0000
12:90971799:CT:C	donor_gain	1.0000
12:90971799:CTT:C	donor_gain	1.0000
12:90971799:CTTT:C	donor_gain	1.0000
12:90971799:CTTTA:C	donor_gain	1.0000
12:90971998:ATCAC:A	acceptor_gain	1.0000
12:90971999:TCAC:T	acceptor_gain	1.0000
12:90972000:CAC:C	acceptor_gain	1.0000
12:90972000:CACC:C	acceptor_gain	1.0000
12:90972001:AC:A	acceptor_gain	1.0000
12:90972002:CC:C	acceptor_gain	1.0000
12:90972003:C:CC	acceptor_gain	1.0000
12:90972007:C:CT	acceptor_gain	1.0000
12:90972008:A:T	acceptor_gain	1.0000
12:90972820:A:AC	donor_gain	1.0000
12:90972821:C:CC	donor_gain	1.0000
12:90972824:A:AC	donor_gain	1.0000
12:90972824:AGG:A	donor_gain	1.0000
12:90972825:G:C	donor_gain	1.0000
12:91002397:TTAC:T	donor_loss	1.0000
12:91002398:TA:T	donor_loss	1.0000
12:91002405:A:C	donor_gain	1.0000
12:91002574:CTTTC:C	acceptor_gain	1.0000

AlphaMissense

2127 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:90964241:C:G	R295P	1.000
12:90970048:A:G	L265P	1.000
12:90964190:C:G	C312S	0.999
12:90964191:A:G	C312R	0.999
12:90964191:A:T	C312S	0.999
12:90964228:G:C	N299K	0.999
12:90964228:G:T	N299K	0.999
12:90964289:C:G	C279S	0.999
12:90964289:C:T	C279Y	0.999
12:90964290:A:G	C279R	0.999
12:90964290:A:T	C279S	0.999
12:90964292:A:C	F278C	0.999
12:90964321:G:C	N268K	0.999
12:90964321:G:T	N268K	0.999
12:90970048:A:T	L265H	0.999
12:90970054:A:G	L263P	0.999
12:90970101:G:C	N247K	0.999
12:90970101:G:T	N247K	0.999
12:90970117:A:G	L242P	0.999
12:90971839:A:C	N221K	0.999
12:90971839:A:T	N221K	0.999
12:90971909:A:G	L198P	0.999
12:90971915:A:G	L196P	0.999
12:90971981:A:G	L174P	0.999
12:90972932:C:G	C130S	0.999
12:90972932:C:T	C130Y	0.999
12:90972933:A:T	C130S	0.999
12:90964170:C:A	G319W	0.998
12:90964175:G:T	P317H	0.998
12:90964187:A:G	L313P	0.998

dbSNP variants (sampled 300 via entrez): RS1000016109 (12:91005926 G>A), RS1000018505 (12:90985058 G>T), RS1000049067 (12:90997238 T>C), RS1000093996 (12:91003020 G>A), RS1000149450 (12:91003327 A>C), RS1000176213 (12:90970495 C>G), RS1000219848 (12:90966928 C>T), RS1000252360 (12:90967194 A>C,G), RS1000275608 (12:90966968 C>A), RS1000399016 (12:90997021 T>C), RS1000452671 (12:90974113 T>C), RS1000585060 (12:90965856 C>A), RS1000826335 (12:90973830 G>A), RS1000899414 (12:90979050 C>G,T), RS1000929486 (12:90978965 G>A,T)

Disease associations

OMIM: gene MIM:601657 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	1
cadmium sulfate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
incobotulinumtoxinA	increases expression	1
Arsenic Trioxide	decreases expression	1
Atrazine	increases expression	1
Benzo(a)pyrene	decreases expression	1
Cycloheximide	decreases expression, decreases reaction	1
Doxorubicin	affects expression	1
Fluorouracil	affects expression	1
T-2 Toxin	decreases expression	1
Tetrachlorodibenzodioxin	decreases expression, decreases reaction	1
Aflatoxin B1	decreases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety